The Future of Genomics and Targeted TherapiesVideo Categories: 2018 AONN Midyear
Dr Andrey Antov muses on the evolution of genomics and how it could potentially impact targeted therapies and cancer care.
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.